Back to list

Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: A sub-analysis of the A1chieve study

Zafar Ahmed Latif a *, Md. Faruque Pathan a, Md. Nazrul Islam Siddiqui b, Md. Javed Sobhan c, Md. Mahfuzur Rahman c and S.M. Ashrafuzzaman a

Diabetes Research and Clinical Practice, pages S30 - S34

Published online Aug-2013

Article view:



To determine the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) therapy in Bangladeshi type 2 diabetes (T2D) patients switched from biphasic human insulin (BHI) as a sub-analysis of the A1chieve study.


Bangladeshi patients switched from BHI to BIAsp 30 at the discretion of their physicians were included. The primary outcome was the incidence of serious adverse drug reactions (SADRs), including major hypoglycaemia. Secondary outcomes comprised changes from baseline to Week 24 in the number of hypoglycaemic events, glycated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), systolic blood pressure and body weight. Quality of life (QoL) was evaluated at baseline and Week 24 using the EQ-5D questionnaire.


A total of 82 patients (mean age ± SD: 52.3±12.2 years; body mass index: 25.6±3.3kg/m2) with a mean diabetes duration of 9.5±5.5 years and mean duration on insulin of 2.5±2.4 years were included. The mean BIAsp 30 dose was 0.49±0.20 U/kg at baseline and 0.47±0.17 U/kg at Week 24. No SADRs were reported. No events of hypoglycaemia (overall, major, minor or nocturnal) were reported at Week 24. Mean HbA1c, FPG and PPPG levels improved by –2.5±1.3%, –65.0±31.8 mg/dL and –119.3±48.7 mg/dL, respectively, over 24 weeks. QoL also improved (mean change from baseline: +28.5±12.9 points).


Switching from BHI to BIAsp 30 therapy improved blood glucose control and was well-tolerated in this Bangladeshi subgroup.

Keywords: Bangladesh, Type 2 diabetes mellitus, Biphasic insulin aspart 30, Biphasic human insulin 30, A1chieve.

Article Outline


  • 1 B Bhowmik, S Binte Munir, I Ara Hossain, T Siddiquee, LM Diep, S Mahmood, et al. Prevalence of type 2 diabetes and impaired glucose regulation with associated cardiometabolic risk factors and depression in an urbanizing rural community in Bangladesh: a population-based cross-sectional study. Diabetes Metab J. 2012;36(6):422-432
  • 2 SN Bleich, TL Koehlmoos, M Rashid, DH Peters, G Anderson. Noncommunicable chronic disease in Bangladesh: overview of existing programs and priorities going forward. Health Policy. 2011;100(2–3):282-289
  • 3 DR Whiting, L Guariguata, C Weil, J Shaw. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-321
  • 4 N Saquib, J Saquib, T Ahmed, MA Khanam, MR Cullen. Cardiovascular diseases and type 2 diabetes in Bangladesh: a systematic review and meta-analysis of studies between 1995 and 2010. BMC Public Health. 2012;12:434
  • 5 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853
  • 6 IM Stratton, AI Adler, HA Neil, DR Matthews, SE Manley, CA Cull, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;32:405-412
  • 7 SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596
  • 8 ZA Latif, A Jain, MM Rahman. Evaluation of management, control, complications and psychosocial aspects of diabetics in Bangladesh: DiabCare Bangladesh 2008. Bangladesh Med Res Counc Bull. 2011;37(1):11-16
  • 9 SG Swinnen, JB Hoekstra, JH DeVries. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S253-S259
  • 10 M Evans, PM Schumm-Oraeger, J Vora, AB King. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13(8):677-684
  • 11 S Halimi, P Raskin, A Liebl, R Kawamori, G Fulcher, G Yan. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther. 2005;27(Suppl B):S57-S74
  • 12 J Davidson, P Vexiau, D Cucinotta, J Vaz, R Kawamori. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther. 2005;27(Suppl B):S75-S88
  • 13 P Home, NE Naggar, M Khamseh, G Gonzalez-Galvez, C Shen, P Chakkarwar, et al. An observational non-interventional study of patients with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011;94:352-363
  • 14 NK Naggar, P Soewondo, ME Khamseh, JW Chen, J Haddad. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A1chieve study. Diabetes Res Clin Pract. 2012;98(3):408-413
  • 15 S Shah, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, et al., IMPROVE Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract. 2009;63(4):574-582
  • 16 M Shestakova, SK Sharma, M Almustafa, KW Min, N Ayad, ST Azar, et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007;23(12):3209-3214
  • 17 PA Khanam, H Mahtab, AU Ahmed, MA Sayeed, AKA Khan. In Bangladesh diabetes starts earlier now than 10 years back: a BIRDEM study. Ibrahim Med Coll J. 2008;2:1-3
  • 18 SG Swinnen, MP Dain, D Mauricio, JH DeVries, JB Hoekstra, F Holleman. Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes Obes Metab. 2010;12(10):923-925
  • 19 A Liebl, V Prusty, P Valensi, R Kawamori, JS Christiansen, AJ Palmer, et al. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings. Drugs. 2012;72(11):1495-1520


a BIRDEM Hospital, Dhaka, Bangladesh BIRDEM Hospital, Dhaka, Bangladesh

b Mymensingh Medical College Hospital, Mymensingh, Bangladesh Mymensingh Medical College Hospital, Mymensingh, Bangladesh

c Novo Nordisk Pharma (Pvt.) Ltd, Dhaka, Bangladesh Novo Nordisk Pharma (Pvt.) Ltd, Dhaka, Bangladesh

* Corresponding author at: Endocrinology, BIRDEM Hospital, 122 Kazi Nazrul Islam Avenue, Shahbagh, Dhaka-1000, Bangladesh

Back to list